Table 2.
Sensitivity of leukemia cell line proliferation to emvododstat.
| Cell Line | Description | Driver Mutation | IC50 (nM) |
|---|---|---|---|
| MOLM-13 | AML heterozygous for the FLT3-ITD | FTL3-ITD (21) | 7.17 |
| Molt4 | T-cell ALL | NOTCH1 (22) NRAS (23) PTEN (23) TP53 (23) |
5.8 |
| U937 | Pro-monocytic, AML | PTEN (24) TP53 (25) |
8 |
| Jurkat | T-cell ALL | BAX (26) NOTCH1 (22) TP53 (27) |
9.4 |
| K562 | Erythroleukemia | BCR-ABL1 (28) TP53 (29) |
11.5 |
| MV4-11 | AML homozygous for the FLT3-ITD | FTL3-ITD (30) | 27 |
| Sup-T1 | T-cell lymphoblastic lymphoma | EGFR (27) TP53 (27) |
28.1 |
| HL60 | APL | NRAS (23) TP53 (31) |
592.5 |
| TF-1 | Erythroleukemia | TP53 (25) | ≥4000 |
| Sup-B15 | B cell precursor ALL | BCR-ABL1 (32) | ≥4000 |
| RS4;11 | ALL that exhibits B lineage and monocytic characteristics | KMT2A-AFF1 (33) | ≥4000 |
| THP-1 | Acute monocytic leukemia | CDKN2A, CDKN2B, PTEN (34), TP73, MLL-AF9 fusion |
≥4000 |
Cells were treated with increasing concentrations of emvododstat (4.57 to 10,000 nM) and were subsequently evaluated for viability after 72 hours using CellTiter-Glo Luminescent Cell Viability Assay kit. The IC50 (concentration resulting in 50% reduction in ATP levels) was determined.